Publication of List of Manufacturers Granted Licence for the Manufacture of Therapeutic Goods - Australian Red Cross Blood Service, SouthPort QLD

Overview

The Therapeutic Goods Act 1989 was enacted to regulate the supply of therapeutic goods in Australia, ensuring that such products are of acceptable quality, safety, and efficacy. This Act was introduced to address the need for a comprehensive legislative framework governing the manufacturing, distribution, and quality control of therapeutic goods. Enacted by the Parliament of Australia, the policy objective of the Act is to protect public health by ensuring that therapeutic goods available in the market are safe, of high quality, and effective for their intended use. The Act provides the Therapeutic Goods Administration with the authority to regulate these goods, including the granting of licenses to manufacturers, such as the Australian Red Cross Blood Service, which was granted a manufacturing license under the Act to ensure that the blood products they produce meet the necessary safety and quality standards.

Scope and Application

The Therapeutic Goods Act 1989 applies to a broad range of therapeutic goods, encompassing medicines, medical devices, blood, and tissues, ensuring that these products are safe, of high quality, and meet acceptable standards of performance. The Act applies to entities and persons involved in the manufacturing, importing, supplying, advertising, and evaluating of therapeutic goods within Australia. The Therapeutic Goods Administration (TGA), which operates under the auspices of the Commonwealth, administers this Act. It extends its jurisdiction to cover all therapeutic goods distributed or intended for distribution within Australia, whether produced locally or imported. The Act delineates certain exclusions, such as over-the-counter vitamins and minerals that meet specific criteria, which are not subject to the same stringent regulatory requirements as other therapeutic goods. Additionally, the Act can be further refined and extended through subordinate instruments, such as regulations and guidelines, which provide more detailed instructions on compliance and enforcement. These subordinate instruments can include specific standards and protocols that must be adhered to by manufacturers and suppliers to ensure the safety and efficacy of therapeutic goods.

Key Provisions

The Therapeutic Goods Act 1989, particularly under Section 38, provides for the licensing of manufacturers of therapeutic goods. Section 38 mandates that the Secretary of the Department of Health, Therapeutic Goods Administration, can grant a licence to a person for the manufacture of therapeutic goods, provided that certain criteria are met. In this instance, the Australian Red Cross Blood Service, an operating division of The Australian Red Cross Society, has been granted such a licence (Section 38). The specific licence number, MI-2013-LI-07257-1, is assigned to the Blood Donor Centre located at Southport, Unit 1/59-61 Ferry Road, Southport, QLD, 4215. The obligations and requirements imposed by the Therapeutic Goods Act 1989 on the licensee, The Australian Red Cross Blood Service, include maintaining high standards of manufacturing quality and compliance with all relevant regulations and guidelines. This ensures that the therapeutic goods produced are safe, effective, and of high quality. The licence mandates that the manufacturing facility adheres to Good Manufacturing Practice (GMP) standards, which encompass all aspects of production from the materials used, to the processes employed, and the facilities and equipment used. Breaches of the conditions set out in the licence or non-compliance with the Therapeutic Goods Act 1989 can result in serious consequences. Under Section 52 of the Act, the Secretary can cancel or suspend a licence if it is found that the holder has contravened any provision of the Act or conditions of the licence. Additionally, under Section 53, the Secretary can take action to prohibit the importation or exportation of therapeutic goods manufactured by the licensee. In more severe cases, breaches may lead to civil or criminal proceedings, including fines and imprisonment. For example, under Section 111, a person found guilty of an offence against the Act may be subject to a fine of up to $220,000 for an individual and $1,100,000 for a body corporate, and/or imprisonment for up to five years. These provisions underscore the importance of strict adherence to the requirements of the Therapeutic Goods Act 1989 by all licensed manufacturers.